HDAC-IN-46

• UNSPSC Description:

  HDAC-IN-46 (compound 12c) is a potent HDAC inhibitor with an IC50 value of 0.21 μM and 0.021 μM for HDAC1 and HDAC6, respectively. HDAC-IN-46 upregulates p-p38, and downregulates Bcl-xL and cyclin D1 in MDA-MB-231 cells. HDAC-IN-46 induces significant G2 phase arrest and apoptosis. HDAC-IN-46 can be used for researching triple-negative breast cancer (TNBC)[1].

• Target Antigen:

  Apoptosis; HDAC

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage;Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/hdac-in-46.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(NO)CCCCCCCN1N=NC(C2=CC=C(C3=C(CC)N=C(N)N=C3N)C=C2)=C1

• Molecular Weight:

  438.53

• References & Citations:

  [1]Wu B, et al. Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity. Bioorg Med Chem. 2020 Mar 15;28(6):115345.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2562386-85-8